$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000123252417000111 Filed on May 09, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$376.1M	$336.0M
YoY Change	11.92%	8.63%
Cost Of Revenue	$25.10M	$23.40M
YoY Change	7.26%	-17.31%
Gross Profit	$348.6M	$310.5M
YoY Change	12.28%	11.39%
Gross Profit Margin	92.7%	92.4%
Selling, General & Admin	$144.3M	$128.8M
YoY Change	12.03%	14.57%
% of Gross Profit	41.38%	41.47%
Research & Development	$44.93M	$31.25M
YoY Change	43.76%	14.98%
% of Gross Profit	12.89%	10.07%
Depreciation & Amortization	$3.130M	$2.527M
YoY Change	23.86%	13.22%
% of Gross Profit	0.9%	0.81%
Operating Expenses	$239.9M	$214.8M
YoY Change	11.67%	11.58%
Operating Profit	$136.1M	$121.2M
YoY Change	12.36%	3.77%
Interest Expense	-$18.84M	-$12.19M
YoY Change	54.56%	-24.95%
% of Operating Profit	-13.84%	-10.06%
Other Income/Expense, Net	-$1.464M	-$819.0K
YoY Change	78.75%	-136.48%
Pretax Income	$115.8M	$108.2M
YoY Change	7.1%	5.25%
Income Tax	$29.16M	$32.34M
% Of Pretax Income	25.17%	29.9%
Net Earnings	$86.51M	$75.81M
YoY Change	14.11%	7.23%
Net Earnings / Revenue	23.01%	22.56%
Basic Earnings Per Share	$1.44	$1.24
Diluted Earnings Per Share	$1.41	$1.21
COMMON SHARES
Basic Shares Outstanding	59.88M shares	61.14M shares
Diluted Shares Outstanding	61.18M shares	62.62M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$407.0M	$980.5M
YoY Change	-58.49%	25.29%
Cash & Equivalents	$347.0M	$979.8M
Short-Term Investments	$60.00M	$800.0K
Other Short-Term Assets	$27.05M	$22.43M
YoY Change	20.6%	4.22%
Inventory	$37.65M	$25.37M
Prepaid Expenses	$38.12M	$18.47M
Receivables	$243.0M	$223.8M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$752.9M	$1.271B
YoY Change	-40.75%	15.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$119.9M	$86.79M
YoY Change	38.17%	21.75%
Goodwill	$899.3M	$671.0M
YoY Change	34.02%	2.52%
Intangibles	$2.999B	$1.348B
YoY Change	122.44%	4.97%
Long-Term Investments
YoY Change
Other Assets	$17.63M	$29.54M
YoY Change	-40.34%	53.96%
Total Long-Term Assets	$4.063B	$2.264B
YoY Change	79.43%	6.08%
TOTAL ASSETS
Total Short-Term Assets	$752.9M	$1.271B
Total Long-Term Assets	$4.063B	$2.264B
Total Assets	$4.816B	$3.535B
YoY Change	36.23%	9.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.14M	$32.62M
YoY Change	-10.66%	19.42%
Accrued Expenses	$183.6M	$307.5M
YoY Change	-40.28%	109.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$136.1M	$37.59M
YoY Change	262.03%	300.43%
Total Short-Term Liabilities	$392.8M	$398.8M
YoY Change	-1.52%	80.81%
LONG-TERM LIABILITIES
Long-Term Debt	$1.740B	$1.146B
YoY Change	51.74%	-14.1%
Other Long-Term Liabilities	$128.8M	$79.21M
YoY Change	62.62%	75.54%
Total Long-Term Liabilities	$1.868B	$1.226B
YoY Change	52.44%	-11.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$392.8M	$398.8M
Total Long-Term Liabilities	$1.868B	$1.226B
Total Liabilities	$2.261B	$1.624B
YoY Change	39.19%	1.51%
SHAREHOLDERS EQUITY
Retained Earnings	$601.5M	$242.4M
YoY Change	148.11%	155.02%
Common Stock	$1.682B	$1.587B
YoY Change	5.99%	6.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.984B	$1.709B
YoY Change
Total Liabilities & Shareholders Equity	$4.816B	$3.535B
YoY Change	36.23%	9.19%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$86.51M	$75.81M
YoY Change	14.11%	7.23%
Depreciation, Depletion And Amortization	$3.130M	$2.527M
YoY Change	23.86%	13.22%
Cash From Operating Activities	$164.5M	$151.7M
YoY Change	8.5%	57.06%
INVESTING ACTIVITIES
Capital Expenditures	-$3.600M	-$11.20M
YoY Change	-67.86%	-22.22%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$800.0K
YoY Change	-100.0%	-102.45%
Cash From Investing Activities	-$3.574M	-$12.00M
YoY Change	-70.2%	-165.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$13.90M	$134.4M
YoY Change	-89.66%	1199.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$181.7M	-$152.5M
YoY Change	19.16%	4575.19%
NET CHANGE
Cash From Operating Activities	$164.5M	$151.7M
Cash From Investing Activities	-$3.574M	-$12.00M
Cash From Financing Activities	-$181.7M	-$152.5M
Net Change In Cash	-$20.71M	-$12.80M
YoY Change	61.79%	-111.47%
FREE CASH FLOW
Cash From Operating Activities	$164.5M	$151.7M
Capital Expenditures	-$3.600M	-$11.20M
Free Cash Flow	$168.1M	$162.9M
YoY Change	3.25%	46.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60028816	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
CY2017Q1	dei	Trading Symbol TradingSymbol	JAZZ
CY2016Q4	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	10139000	USD
CY2017Q1	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	10897000	USD
CY2016Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	1597000	USD
CY2017Q1	jazz	Accrued Construction In Progress AccruedConstructionInProgress	3484000	USD
CY2016Q4	jazz	Accrued Contract Termination Fees Current AccruedContractTerminationFeesCurrent	11612000	USD
CY2017Q1	jazz	Accrued Contract Termination Fees Current AccruedContractTerminationFeesCurrent	0	USD
CY2016Q4	jazz	Accrued Interest AccruedInterest	5179000	USD
CY2017Q1	jazz	Accrued Interest AccruedInterest	2356000	USD
CY2016Q4	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	3350000	USD
CY2017Q1	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	4003000	USD
CY2016Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	72344000	USD
CY2017Q1	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	73949000	USD
CY2016Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2017Q1	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2016Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	23439000	USD
CY2017Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	25065000	USD
CY2016Q4	jazz	Entity Wide Accounts Receivable Major Customers Percentage EntityWideAccountsReceivableMajorCustomersPercentage	0.90
CY2017Q1	jazz	Entity Wide Accounts Receivable Major Customers Percentage EntityWideAccountsReceivableMajorCustomersPercentage	0.88
CY2016Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2017Q1	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2016Q4	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2017Q1	jazz	Number Of Customers With Significant Accounts Receivable Balance NumberOfCustomersWithSignificantAccountsReceivableBalance	5	Customer
CY2017Q1	jazz	Number Of Patents Covered In Instructions NumberOfPatentsCoveredInInstructions	3	patent
CY2016Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	8750000	USD
CY2017Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	0	USD
CY2016Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	898000	USD
CY2017Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	948000	USD
CY2016Q1	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2094000	USD
CY2017Q1	jazz	Royalties And Contract Revenues RoyaltiesAndContractRevenues	2375000	USD
CY2016Q4	jazz	Sales Return Reserve SalesReturnReserve	4366000	USD
CY2017Q1	jazz	Sales Return Reserve SalesReturnReserve	4145000	USD
CY2016Q1	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	3780000	USD
CY2017Q1	jazz	Stock Issued During Period Employee Plansand Warrants Exercises StockIssuedDuringPeriodEmployeePlansandWarrantsExercises	5676000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22415000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	29144000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	234244000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	243035000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	43363000	USD
CY2017Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	35914000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193268000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	183645000	USD
CY2016Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3924000	USD
CY2017Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	4467000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4596000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6192000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	11643000	USD
CY2017Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7486000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32142000	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34822000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-317333000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-299843000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1665232000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1681774000	USD
CY2016Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	12476000	USD
CY2017Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	14431000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24608000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25297000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24183000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25193000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	17250000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	17569000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5362000	USD
CY2017Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5615000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22642000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25665000	USD
CY2016Q4	us-gaap	Assets Assets	4800227000	USD
CY2017Q1	us-gaap	Assets Assets	4815824000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	748069000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	752853000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	425963000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	406995000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	425963000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	406995000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	988785000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	979780000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	365963000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	346995000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9005000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18968000	USD
CY2017Q1	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	-2000000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	121000000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	104001000	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1978828000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9737000	USD
CY2017Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9325000	USD
CY2016Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	15060000	USD
CY2017Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	18038000	USD
CY2016Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5742000	USD
CY2017Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15000000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	556733000	USD
CY2017Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	548038000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1123000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8590000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2601000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	22624000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	2527000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	3130000	USD
CY2017Q1	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	1671000	USD
CY2017Q1	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	2471000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.21
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.41
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	3794000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	1740000	USD
CY2016Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.299
CY2017Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.252
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y0M0D
CY2016Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	6933000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	7624000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	421687000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	450980000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	580258000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	77309000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	98044000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	98980000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	100123000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	100336000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1491768000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1506030000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1070081000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1055050000	USD
CY2017Q1	us-gaap	Gain Loss On Cash Flow Hedge Ineffectiveness Net GainLossOnCashFlowHedgeIneffectivenessNet	100000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-37000	USD
CY2017Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-82000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	893810000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	899290000	USD
CY2017Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	5480000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	108151000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	115832000	USD
CY2016Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2017Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-161000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32339000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29160000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10664000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5865000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13802000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8483000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	25758000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	30753000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6706000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15743000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-266000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	27490000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6307000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4258000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-104000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2170000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	7392000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8174000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1231000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10637000	USD
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1474000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1298000	shares
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3433688000	USD
CY2017Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3449760000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3012001000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2998780000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12192000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-18844000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13815000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17418000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	34051000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	37653000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1547000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2798000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	18689000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	17437000	USD
CY2016Q4	us-gaap	Investments Investments	60000000	USD
CY2017Q1	us-gaap	Investments Investments	60000000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4800227000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4815824000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	257406000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	392773000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	2029625000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	1875688000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	36094000	USD
CY2017Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	136094000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1775801000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	76700000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	58652000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	40605000	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	27070000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1993531000	USD
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1739594000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-152458000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-181674000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11995000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3574000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	151654000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	164540000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	75812000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	86511000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	214848000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	239913000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	121162000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	136140000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	122089000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	9464000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	9556000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	10825000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	12243000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	68028000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	11973000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21155000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30752000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	29310000	USD
CY2017Q1	us-gaap	Other Assets Current OtherAssetsCurrent	27052000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14060000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17625000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	45188000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	18112000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	45188000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	17490000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-622000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-89000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	112617000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	128809000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1579000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1405000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-819000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1464000	USD
CY2016Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	60000000	USD
CY2017Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	60000000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	134365000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13896000	USD
CY2016Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	12476000	USD
CY2017Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14431000	USD
CY2016Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	773000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2016Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2472000	USD
CY2017Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3574000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	24501000	USD
CY2017Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38118000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3780000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5676000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	139632000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	154735000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	107490000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	119913000	USD
CY2016Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2017Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	150000000	USD
CY2016Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	9397000	USD
CY2017Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	9023000	USD
CY2016Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	8750000	USD
CY2017Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31252000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44928000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	528907000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	601522000	USD
CY2016Q1	us-gaap	Revenues Revenues	336010000	USD
CY2017Q1	us-gaap	Revenues Revenues	376053000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	333916000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	373678000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	128765000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	144255000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24183000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25193000	USD
CY2016Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	134365000	USD
CY2017Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13896000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	1706333000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	1708880000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1877339000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	1983986000	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4506000	USD
CY2017Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	35300000	USD
CY2017Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	31900000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62616000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61178000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61142000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59880000	shares
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had foreign exchange forward contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$148.9 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the net fair value of outstanding foreign exchange forward contracts was not significant. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had interest rate swap contracts with notional amounts totaling </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">. These outstanding interest rate swap contracts had a net liability fair value of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> was included in other non-current assets and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> was included in accrued liabilities as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not material.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable, and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;">88%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, including Express Scripts Specialty Distribution Services, Inc. and its affiliates, or Express Scripts, which accounted for </font><font style="font-family:inherit;font-size:10pt;">69%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and McKesson Corporation and affiliates, which accounted for </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;">90%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, including Express Scripts, which accounted for </font><font style="font-family:inherit;font-size:10pt;">73%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and McKesson Corporation and affiliates, which accounted for </font><font style="font-family:inherit;font-size:10pt;">13%</font><font style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend on single source suppliers for most of our products, product candidates and their APIs. We commenced manufacturing of Xyrem in our Ireland facility in the third quarter of 2016.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001232524-17-000111-index-headers.html	Edgar Link	pending
0001232524-17-000111-index.html	Edgar Link	pending
0001232524-17-000111.txt	Edgar Link	pending
0001232524-17-000111-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20170331.xml	Edgar Link	completed
jazz-20170331.xsd	Edgar Link	pending
jazz-20170331_cal.xml	Edgar Link	unprocessable
jazz-20170331_def.xml	Edgar Link	unprocessable
jazz-20170331_lab.xml	Edgar Link	unprocessable
jazz-20170331_pre.xml	Edgar Link	unprocessable
jazz2017q1doc.htm	Edgar Link	pending
jazzq12017ex311.htm	Edgar Link	pending
jazzq12017ex312.htm	Edgar Link	pending
jazzq12017ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2017 Q1 Form 10-Q Financial Statement

#000123252417000111 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2017 Q1 Form 10-Q Financial Statement

#000123252417000111 Filed on May 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz